These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 22882703)
1. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Warth A; Muley T; Herpel E; Meister M; Herth FJ; Schirmacher P; Weichert W; Hoffmann H; Schnabel PA Histopathology; 2012 Dec; 61(6):1017-25. PubMed ID: 22882703 [TBL] [Abstract][Full Text] [Related]
2. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Whithaus K; Fukuoka J; Prihoda TJ; Jagirdar J Arch Pathol Lab Med; 2012 Feb; 136(2):155-62. PubMed ID: 22288962 [TBL] [Abstract][Full Text] [Related]
4. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. Kim MJ; Shin HC; Shin KC; Ro JY Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737 [TBL] [Abstract][Full Text] [Related]
5. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Mukhopadhyay S; Katzenstein AL Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283 [TBL] [Abstract][Full Text] [Related]
6. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung. Argon A; Nart D; Veral A Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390 [TBL] [Abstract][Full Text] [Related]
7. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. Tsuta K; Tanabe Y; Yoshida A; Takahashi F; Maeshima AM; Asamura H; Tsuda H J Thorac Oncol; 2011 Jul; 6(7):1190-9. PubMed ID: 21623236 [TBL] [Abstract][Full Text] [Related]
8. The role of the cytopathologist in subtyping and epidermal growth factor receptor testing in non-small cell lung cancer: An institutional experience. Sekar A; Gupta N; Rajwanshi A; Chaturvedi R; Singh N; Lal A Cytopathology; 2017 Oct; 28(5):371-377. PubMed ID: 28730709 [TBL] [Abstract][Full Text] [Related]
9. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475 [TBL] [Abstract][Full Text] [Related]
10. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Sterlacci W; Savic S; Schmid T; Oberaigner W; Auberger J; Fiegl M; Tzankov A Am J Clin Pathol; 2012 Jun; 137(6):946-56. PubMed ID: 22586054 [TBL] [Abstract][Full Text] [Related]
11. The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung. van Zyl A; Schubert PT; Koegelenberg CFN Cytopathology; 2019 Nov; 30(6):586-591. PubMed ID: 31206846 [TBL] [Abstract][Full Text] [Related]
12. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas. Noh S; Shim H Lung Cancer; 2012 Apr; 76(1):51-5. PubMed ID: 21978426 [TBL] [Abstract][Full Text] [Related]
13. Chromogenic immunohistochemical quadruplex provides accurate diagnostic differentiation of non-small cell lung cancer. Roberts EA; Morrison LE; Behman LJ; Draganova-Tacheva R; O'Neill R; Solomides CC Ann Diagn Pathol; 2020 Apr; 45():151454. PubMed ID: 31923744 [TBL] [Abstract][Full Text] [Related]
14. Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: utility of an immunohistochemical panel containing CK5/6, CK34βE12, p63, CK7 and TTF-1. Xu XY; Yang GY; Yang JH; Li J Pathol Res Pract; 2014 Oct; 210(10):680-5. PubMed ID: 25063315 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Rekhtman N; Ang DC; Sima CS; Travis WD; Moreira AL Mod Pathol; 2011 Oct; 24(10):1348-59. PubMed ID: 21623384 [TBL] [Abstract][Full Text] [Related]
16. Ribonucleic Acid In Situ Hybridization Is a More Sensitive Method Than Immunohistochemistry in Detection of Thyroid Transcription Factor 1 and Napsin A Expression in Lung Adenocarcinomas. Shi J; Liu H; Ma XJ; Chen Z; He MX; Luo Y; Lin F Arch Pathol Lab Med; 2016 Apr; 140(4):332-40. PubMed ID: 27028392 [TBL] [Abstract][Full Text] [Related]
17. ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Zhao W; Wang H; Peng Y; Tian B; Peng L; Zhang DC Int J Clin Exp Pathol; 2014; 7(7):4247-53. PubMed ID: 25120805 [TBL] [Abstract][Full Text] [Related]
18. A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. Koh J; Go H; Kim MY; Jeon YK; Chung JH; Chung DH Histopathology; 2014 Dec; 65(6):868-78. PubMed ID: 25130792 [TBL] [Abstract][Full Text] [Related]
19. Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer. Koyi H; Brandén E; Kasim I; Wilander E Anticancer Res; 2018 Jun; 38(6):3341-3346. PubMed ID: 29848682 [TBL] [Abstract][Full Text] [Related]